WASHINGTON, Sept. 29, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced participation
October 9, 2017
Abstract 1455: "Tasimelteon improves symptoms of major depression in an African American population."
October 11, 2017
Abstract 1539: "Tasimelteon improves sleep quality and behavior in individuals with Smith-Magenis syndrome (SMS) in an open-label study."
Abstract 1543: "Differences in the timing of melatonin secretion between African American and Caucasian patients with major depressive disorder."
Abstract 1454: "Estimating burden of disease among blind individuals with non 24 hour sleep wake disorder."
For more information on World Sleep 2017, please refer to http://worldsleepcongress.com/
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.
Jim KellyExecutive Vice President and Chief Financial Officer Vanda Pharmaceuticals Inc. (202) [email protected]
View original content:http://www.prnewswire.com/news-releases/vanda-to-present-scientific-posters-at-world-sleep-2017-300528391.html
SOURCE Vanda Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...View All